2025年ASCO计划_71页_2mb

2025 ASCO Annual Meeting Planner Summary

Core Information

• Event: 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• Location: Chicago, Illinois
• Dates: May 30 - June 3, 2025
• Planner Provided By: Biomedtracker and Datamonitor Healthcare
• Focus Areas: Cancer care delivery, disease-specific research, and innovative therapeutic approaches

Key Sessions and Presentations

Friday, May 30th

Oral Abstract Session: Quality Care/Health Services Research

• Location: $504 | Live Stream (1:00 PM - 4:00 PM)
• Presentations:
  • 1:00 PM: Psychosocial digital application for caregivers of patients undergoing HSCT: A randomized controlled trial. First Author: Jamie M. Jacobs, PhD
  • 1:12 PM: Outcomes of an ePRO-based symptom management program: A cluster randomized trial. First Author: Michael J. Hassett, MD, MPH, FASCO
  • 1:24 PM: Improving care of older adults with cancer: A randomized trial. First Author: Manali I. Patel, MD, MPH, MS, FASCO
  • 1:36 PM: Supportive oncology care at home for patients with cancer receiving curative treatment: A randomized trial. First Author: Ryan David Nipp, MD, FASCO
  • 1:48 PM: Try This, Not That: Interventions to Boost How Patients Feel, Where They're At. First Author: Robert Michael Daly, MD, MBA, FASCO
  • 2:00 PM: Panel Question and Answer
  • 2:12 PM: Empowering young-onset colorectal cancer patients with an online platform for germline testing. First Author: Julie B Moskowitz, MS
  • 2:24 PM: Real-world SDOH and outcomes of early-onset CRC: Analysis of a large US community oncology network. First Author: Jessica Paulus, ScD
  • 2:36 PM: Too Soon, Too Fast: Addressing early-onset colorectal cancer. First Author: Michael J. Raphael, FRCP, MSc
  • 2:48 PM: Panel Question and Answer
  • 3:00 PM: Association of Medicaid expansion with 5-year survival after cancer diagnosis. First Author: Elizabeth Schafer, MPH
  • 3:12 PM: Pragmatic interventions to improve mammogram uptake in non-compliant populations. First Author: Sasidharan Swarnalatha Lucky, PhD
  • 3:24 PM: Too Many Rules, Too Many Traps: Can policy close the gaps? First Author: Mya Robinson, PhD
  • 3:36 PM: Panel Question and Answer

Rapid Oral Abstract Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

• Location: E450a | On Demand (1:00 PM - 2:30 PM)
• Presentations:
  • 1:00 PM: Phase I study of ascininib in combination with dasatinib, prednisone, and blinatumomab for Ph+ adult leukemia. Drug: Scemblix, Sprycel, Blincyto Company: Novartis, Bristol Myers Squibb, Amgen First Author: Marilise R Luskin, MD
  • 1:06 PM: MRD negativity after end of induction in the PHALLCON trial: Post hoc analysis. Drug: Iclusig Company: Takeda First Author: Ibrahim Aldoss, MD
  • 1:12 PM: Reduced dose PTCy in AML patients receiving matched unrelated donor HSCT. First Author: Nihar Desai, MD, DM
  • 1:18 PM: Panel Question and Answer
  • 1:30 PM: OS and duration of response in MDS patients treated with luspatercept vs epoetin alfa. Drug: Reblozyl Company: Merck & Co. First Author: Guillermo Garcia-Manero, MD
  • 1:36 PM: Efficacy of bexmarilimab + azacitidine in MDS. Drug: bexmarilimab Company: Faron Pharmaceuticals First Author: Naval Guastad Daver, MD
  • 1:42 PM: Dosing of Vendexta for TP53 mutant MDS and AML. First Author: Mendel Goldfinger, MD
  • 1:48 PM: Panel Question and Answer
  • 2:00 PM: IMproveMF update: IME + RUX in MF patients. Drug: Rytelo, Jakafi Company: Geron, Incyte First Author: John Mascarenhas, MD
  • 2:06 PM: Efficacy and safety of ascinimib in CML-CP after 1 TKI. Drug: Scemblix Company: Novartis First Author: David Jacob Andorsky, MD
  • 2:12 PM: Age-related macular degeneration in individuals with clonal hematopoiesis. First Author: Keishla Marie Arce-Ruiz, BS
  • 2:18 PM: Panel Question and Answer

Friday, May 30th - Continued

Oral Abstract Session: Gastrointestinal Cancer—Colorectal and Anal

• Location: Arie Crown Theater | Live Stream (2:45 PM - 5:45 PM)
• Presentations:
  • 2:45 PM: First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant mCRC. Drug: Braftovi, Erbitux Company: Pfizer, Eli Lilly First Author: Elena Elez, MD, PhD
  • 2:57 PM: Nivolumab + piliimplumab vs chemo or NIVO in MSI-H/dMMR mCRC. Drug: Opdivo, Yervoy Company: Bristol Myers Squibb First Author: Heinz-Josef Lenz, MD, PhD
  • 3:09 PM: Anlotinib vs bevacizumab in RAS/BRAF wild-type mCRC. Drug: Anlotinib Company: Advenchin Laboratories First Author: Ke-Feng Ding, MD, PhD
  • 3:21 PM: Precision Oncology in the First-Line Setting of Colorectal Cancer First Author: Andrea Sartore-Bianchi, MD
  • 3:33 PM: Panel Question and Answer
  • 3:45 PM: Panel Question and Answer
  • 3:57 PM: TQB2102 in advanced solid tumors. Drug: TQB-2102 Company: Chia Tai Tianqing Pharmaceutical Group First Author: Rui-Hua Xu, MD, PhD
  • 4:09 PM: DLT observation in VMT-NET trial. Drug: VMT - NET Company: Perspective Therapeutics First Author: Thorvardur Ragner Halfdanarson, MD
  • 4:21 PM: To BITE or to Go Nuclear? New Hope for First Author: Heloise P. Soares, MD
  • 4:33 PM: Panel Question and Answer
  • 4:45 PM: ctDNA profiling in less common cancers. First Author: Biswajit Das, PhD
  • 4:57 PM: Ultra-sensitive ctDNA molecular residual disease assessment. First Author: Tadayoshi Hashimoto, MD, PhD
  • 5:09 PM: ctDNA in HR+HER2-negative breast cancer treated with NET. First Author: Silver Alkhafaji, BS
  • 5:21 PM: I-SPY a MONSTAR MATCH: Is It written in Blood? First Author: Emil Lou, MD, PhD
  • 5:33 PM: Panel Question and Answer

Friday, May 30th - Continued

Oral Abstract Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

• Location: S100a | Live Stream (2:45 PM - 5:45 PM)
• Presentations:
  • 2:45 PM: ctDNA-MRD by Phased-Seq in DLBCL patients. First Author: Steven Wang, MD
  • 2:57 PM: Revised staging system for NK T-cell lymphoma. First Author: Tongyu Lin, MD, PhD
  • 3:09 PM: Molecular landscape of follicular lymphoma histologic grades. First Author: Cong Sun, MS
  • 3:21 PM: Moving the Needle: Improving clinical and molecular risk stratification in lymphoma. First Author: Mark J. Roschewski, MD
  • 3:33 PM: Panel Question and Answer
  • 3:45 PM: Phase 1 study of KITE-363 in R/R B-cell lymphoma. Drug: KITE-363 Company: Gilead Sciences First Author: Saurabh Dahiya, MD, FACP
  • 3:57 PM: Multi-virus specific T cells to enhance bispecific antibody activity in lymphoma. First Author: Akiwa Diamond, MD
  • 4:09 PM: WaveLINE-003: Zilovertamab vedotin + SOC in R/R DLBCL. Drug: Zilovertamab vedotin Company: Merck & Co. First Author: Philippe Armand, MD, PhD
  • 4:21 PM: Strengthening the Strike: Novel treatment approaches in R/R large B-cell lymphoma. First Author: Paolo Fabrizio Caimi, MD
  • 4:33 PM: Panel Question and Answer
  • 4:45 PM: Sintilimab + chidamide + P-GemOx in TN-ENKTL. Drug: Sintilimab, Hiyasta Company: Innovent Biologics, HUYA Bioscience First Author: Huiqiang Huang, MD, PhD
  • 4:57 PM: Sintilimab + ICE in second-line cHL. Drug: Sintilimab Company: Innovent Biologics First Author: Peng Liu
  • 5:09 PM: Completed dose-finding part of phase 2 study of acimitamig + AlloNK in cHL. Drug: Acimitamig Company: Affimed First Author: Joseph E. Maakaron, MD
  • 5:21 PM: Reinventing Immunotherapy in Hodgkin Lymphoma and ENKTL First Author: Sarah C Rutherford, MD
  • 5:33 PM: Panel Question and Answer

Saturday, May 31st

Rapid Oral Abstract Session: Care Delivery/Models of Care

• Location: $402 | On Demand (8:00 AM - 9:30 AM)
• Presentations:
  • 8:00 AM: Anesthesia type in biologically aggressive cancers. First Author: Elliott Bennett Guerrero, MD
  • 8:06 AM: General practitioner-led vs surgeon-led colon cancer survivorship care. First Author: Julien Vos, PhD
  • 8:12 AM: Post-discharge symptom monitoring and hospital readmissions. First Author: Robert Michael Daly, MD, MBA, FASCO
  • 8:18 AM: Panel Question and Answer
  • 8:30 AM: Economic modeling for immune checkpoint inhibitors in LMICs. First Author: Giulia Segafredo, PhD
  • 8:36 AM: Major adverse financial events and mortality risk before cancer diagnosis. First Author: Robin Yabroff, PhD, MBA
  • 8:42 AM: Broad-based genomic sequencing and survival in advanced NSCLC. First Author: Patricia Mae Garcia Santos, MD, MS
  • 8:48 AM: Panel Question and Answer

Clinical Science Symposium: The Future of Cancer Detection Is Coming

• Location: Hall D1 | Live Stream (8:00 AM - 9:30 AM)
• Presentations:
  • 8:00 AM: Is it as easy as a blood test? First Author: Scott David Ramsey, MD, PhD
  • 8:12 AM: Promise and Pitfalls: A patient's view on blood-based cancer tests. First Author: Jane Perlmutter, PhD, FASCO, MBA
  • 8:24 AM: Performance evaluation of a methylated ctDNA multi-cancer early detection test in individuals with obesity. First Author: Dax Kurbegov, MD, FASCO
  • 8:36 AM: Prognostic significance of blood-based multi-cancer detection in ctDNA. First Author: Matthew Margolis, BS, MSc
  • 8:48 AM: Assay Showdown: Comparing cutting-edge blood tests for cancer detection. First Author: Maximilian Diehn, MD, PhD, FASCO
  • 9:00 AM: From Promise to Practice: Clinical future of blood-based cancer assays. First Author: Marie Wood, MD, FASCO, FACP
  • 9:12 AM: Panel Question and Answer

Main Themes and Insights

• Health Services Research: Focus on improving patient care through digital tools, symptom management, and addressing disparities in treatment outcomes.
• Hematologic Malignancies: Highlighted the role of novel therapies, such as CAR T-cell therapy, bispecific antibodies, and targeted agents, in improving outcomes for patients with leukemia, MDS, and lymphoma.
• Gastrointestinal Cancer: Emphasis on the use of targeted therapies, such as BRAF inhibitors, and the importance of ctDNA in guiding treatment and assessing outcomes.
• Cancer Detection and Personalized Medicine: Exploration of blood-based tests for early detection, particularly in the context of obesity and multi-cancer screening.
• Care Models: Investigation into the effectiveness of different care delivery models, including the role of GPs and the impact of post-discharge monitoring on hospital readmissions.

Key Takeaways

• The 2025 ASCO Annual Meeting features a wide range of presentations covering various aspects of cancer care, from clinical trials to health policy and digital health tools.
• There is a strong focus on precision oncology, innovative treatment approaches, and the integration of real-world data into clinical decision-making.
• The meeting also addresses the importance of patient-centered care, health disparities, and the role of technology in improving cancer outcomes.